Global Human Fibrinogen

Human Fibrinogen Comprehensive Study by Fibrinogen Test Results (Normal Results, Abnormal Results), End Users (Congenital Fibrinogen Deficiency, Surgical Procedures), Fibrinogen Deficiency (Afibrinogenemia, Dysfibrinogenemia, Hypofibrinogenemia) Players and Region - Global Market Outlook to 2030

Human Fibrinogen Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 15.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Human Fibrinogen
Fibrinogen is a glycoprotein complex in the blood involved in the blood clotting process. During a tissue or vascular injury, the fibrinogen is converted into fibrin with the help of enzymes such as thrombin which leads to blood clotting in order to prevent blood loss. The fibrin stops bleeding by closing up the blood vessels. Fibrinogen is a plasma glycoprotein with a molecular weight of 340 kDa; it is synthesized by the liver. The conversion of fibrinogen to fibrin is catalyzed by thrombin and plays a key role in clot formation and stabilization. In addition, fibrinogen induces platelet activation and aggregation by binding to the platelet fibrinogen receptor glycoprotein Check more insightful analysis on "Fibrinogen Concentrates Market Share & Industry Growth Analysis".

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR15.5%


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Human Fibrinogen market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

CSL Behring(United States), Green Cross Corp. (South Korea), Octapharma AG (Switzerland), LFB S.A (France), Shanghai Xinxing Medicine Co Ltd(China), Harbin Pacific Biopharmaceutical Co. Ltd. (China), ProFibrix B.V.( Netherlands), Shanghai Raas Blood Products Co. Ltd(China) and Baxter International Inc.( United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Human Fibrinogen market by and Region.



On the basis of geography, the market of Human Fibrinogen has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Fibrinogen Test Results, the sub-segment i.e. Normal Results will boost the Human Fibrinogen market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Users, the sub-segment i.e. Congenital Fibrinogen Deficiency will boost the Human Fibrinogen market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Fibrinogen Deficiency, the sub-segment i.e. Afibrinogenemia will boost the Human Fibrinogen market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Several launches and approvals of new fibrinogen concentrates are expected to boost growth

Market Growth Drivers:
The factors such as an increase in the use of human fibrinogen in bleeding patients and for the treatment of congenital deficiencies drive, the growth of the global market. Moreover and The rise in awareness and concerns pertaining to health boots the growth of the market

Challenges:
High product development costs

Restraints:
Intellectual property rights regulatory requirement

Opportunities:
The rise in the number of market players are targeting developing fibrinogen concentrates to treat the bleeding incidences in patients with congenital fibrinogenemia

Market Leaders and their expansionary development strategies
In June 2023, Cardinal Health (NYSE: CAH) today announced it has signed a definitive agreement to contribute its Outcomes™ business to Transaction Data Systems (TDS), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a minority stake in the combined entity. Under the terms of the agreement, Cardinal Health's pharmaceutical segment CEO, Debbie Weitzman, will be appointed to the TDS board of directors.
On Feb. 14, 2024, Grifols one of the world’s leading producers of plasma-derived medicines, today announced that Biotest’s positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate (FC), BT524, advance this potential treatment for acquired fibrinogen deficiency (AFD), an underserved growth market.
“BLA for Fibrinogen (Human) effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Fibrinogen (Human) under your existing Department of Health and Human Services U.S. License No. 1646. Fibrinogen (Human) is indicated for the treatment of acute bleeding episodes in adults and adolescents ≥ 12 years of age with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.”

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Human Fibrinogen Manufacturer, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Fibrinogen Test Results
  • Normal Results
  • Abnormal Results

By End Users
  • Congenital Fibrinogen Deficiency
  • Surgical Procedures

By Fibrinogen Deficiency
  • Afibrinogenemia
  • Dysfibrinogenemia
  • Hypofibrinogenemia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The factors such as an increase in the use of human fibrinogen in bleeding patients and for the treatment of congenital deficiencies drive
      • 3.2.2. The growth of the global market. Moreover
      • 3.2.3. The rise in awareness and concerns pertaining to health boots the growth of the market
    • 3.3. Market Challenges
      • 3.3.1. High product development costs
    • 3.4. Market Trends
      • 3.4.1. Several launches and approvals of new fibrinogen concentrates are expected to boost growth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Fibrinogen, by Fibrinogen Test Results, End Users, Fibrinogen Deficiency and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human Fibrinogen (Value)
      • 5.2.1. Global Human Fibrinogen by: Fibrinogen Test Results (Value)
        • 5.2.1.1. Normal Results
        • 5.2.1.2. Abnormal Results
      • 5.2.2. Global Human Fibrinogen by: End Users (Value)
        • 5.2.2.1. Congenital Fibrinogen Deficiency
        • 5.2.2.2. Surgical Procedures
      • 5.2.3. Global Human Fibrinogen by: Fibrinogen Deficiency (Value)
        • 5.2.3.1. Afibrinogenemia
        • 5.2.3.2. Dysfibrinogenemia
        • 5.2.3.3. Hypofibrinogenemia
      • 5.2.4. Global Human Fibrinogen Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Human Fibrinogen: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CSL Behring(United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Green Cross Corp. (South Korea)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Octapharma AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. LFB S.A (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shanghai Xinxing Medicine Co Ltd(China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Harbin Pacific Biopharmaceutical Co. Ltd. (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ProFibrix B.V.( Netherlands)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Shanghai Raas Blood Products Co. Ltd(China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Baxter International Inc.( United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Human Fibrinogen Sale, by Fibrinogen Test Results, End Users, Fibrinogen Deficiency and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human Fibrinogen (Value)
      • 7.2.1. Global Human Fibrinogen by: Fibrinogen Test Results (Value)
        • 7.2.1.1. Normal Results
        • 7.2.1.2. Abnormal Results
      • 7.2.2. Global Human Fibrinogen by: End Users (Value)
        • 7.2.2.1. Congenital Fibrinogen Deficiency
        • 7.2.2.2. Surgical Procedures
      • 7.2.3. Global Human Fibrinogen by: Fibrinogen Deficiency (Value)
        • 7.2.3.1. Afibrinogenemia
        • 7.2.3.2. Dysfibrinogenemia
        • 7.2.3.3. Hypofibrinogenemia
      • 7.2.4. Global Human Fibrinogen Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Fibrinogen: by Fibrinogen Test Results(USD Million)
  • Table 2. Human Fibrinogen Normal Results , by Region USD Million (2018-2023)
  • Table 3. Human Fibrinogen Abnormal Results , by Region USD Million (2018-2023)
  • Table 4. Human Fibrinogen: by End Users(USD Million)
  • Table 5. Human Fibrinogen Congenital Fibrinogen Deficiency , by Region USD Million (2018-2023)
  • Table 6. Human Fibrinogen Surgical Procedures , by Region USD Million (2018-2023)
  • Table 7. Human Fibrinogen: by Fibrinogen Deficiency(USD Million)
  • Table 8. Human Fibrinogen Afibrinogenemia , by Region USD Million (2018-2023)
  • Table 9. Human Fibrinogen Dysfibrinogenemia , by Region USD Million (2018-2023)
  • Table 10. Human Fibrinogen Hypofibrinogenemia , by Region USD Million (2018-2023)
  • Table 11. South America Human Fibrinogen, by Country USD Million (2018-2023)
  • Table 12. South America Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 13. South America Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 14. South America Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 15. Brazil Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 16. Brazil Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 17. Brazil Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 18. Argentina Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 19. Argentina Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 20. Argentina Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 21. Rest of South America Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 22. Rest of South America Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 23. Rest of South America Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 24. Asia Pacific Human Fibrinogen, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 26. Asia Pacific Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 27. Asia Pacific Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 28. China Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 29. China Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 30. China Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 31. Japan Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 32. Japan Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 33. Japan Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 34. India Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 35. India Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 36. India Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 37. South Korea Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 38. South Korea Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 39. South Korea Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 40. Taiwan Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 41. Taiwan Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 42. Taiwan Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 43. Australia Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 44. Australia Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 45. Australia Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 49. Europe Human Fibrinogen, by Country USD Million (2018-2023)
  • Table 50. Europe Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 51. Europe Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 52. Europe Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 53. Germany Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 54. Germany Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 55. Germany Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 56. France Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 57. France Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 58. France Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 59. Italy Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 60. Italy Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 61. Italy Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 62. United Kingdom Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 63. United Kingdom Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 64. United Kingdom Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 65. Netherlands Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 66. Netherlands Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 67. Netherlands Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 68. Rest of Europe Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 69. Rest of Europe Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 70. Rest of Europe Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 71. MEA Human Fibrinogen, by Country USD Million (2018-2023)
  • Table 72. MEA Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 73. MEA Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 74. MEA Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 75. Middle East Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 76. Middle East Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 77. Middle East Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 78. Africa Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 79. Africa Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 80. Africa Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 81. North America Human Fibrinogen, by Country USD Million (2018-2023)
  • Table 82. North America Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 83. North America Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 84. North America Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 85. United States Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 86. United States Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 87. United States Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 88. Canada Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 89. Canada Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 90. Canada Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 91. Mexico Human Fibrinogen, by Fibrinogen Test Results USD Million (2018-2023)
  • Table 92. Mexico Human Fibrinogen, by End Users USD Million (2018-2023)
  • Table 93. Mexico Human Fibrinogen, by Fibrinogen Deficiency USD Million (2018-2023)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Human Fibrinogen: by Fibrinogen Test Results(USD Million)
  • Table 104. Human Fibrinogen Normal Results , by Region USD Million (2025-2030)
  • Table 105. Human Fibrinogen Abnormal Results , by Region USD Million (2025-2030)
  • Table 106. Human Fibrinogen: by End Users(USD Million)
  • Table 107. Human Fibrinogen Congenital Fibrinogen Deficiency , by Region USD Million (2025-2030)
  • Table 108. Human Fibrinogen Surgical Procedures , by Region USD Million (2025-2030)
  • Table 109. Human Fibrinogen: by Fibrinogen Deficiency(USD Million)
  • Table 110. Human Fibrinogen Afibrinogenemia , by Region USD Million (2025-2030)
  • Table 111. Human Fibrinogen Dysfibrinogenemia , by Region USD Million (2025-2030)
  • Table 112. Human Fibrinogen Hypofibrinogenemia , by Region USD Million (2025-2030)
  • Table 113. South America Human Fibrinogen, by Country USD Million (2025-2030)
  • Table 114. South America Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 115. South America Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 116. South America Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 117. Brazil Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 118. Brazil Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 119. Brazil Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 120. Argentina Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 121. Argentina Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 122. Argentina Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 123. Rest of South America Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 124. Rest of South America Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 125. Rest of South America Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 126. Asia Pacific Human Fibrinogen, by Country USD Million (2025-2030)
  • Table 127. Asia Pacific Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 128. Asia Pacific Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 129. Asia Pacific Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 130. China Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 131. China Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 132. China Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 133. Japan Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 134. Japan Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 135. Japan Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 136. India Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 137. India Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 138. India Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 139. South Korea Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 140. South Korea Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 141. South Korea Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 142. Taiwan Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 143. Taiwan Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 144. Taiwan Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 145. Australia Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 146. Australia Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 147. Australia Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 148. Rest of Asia-Pacific Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 149. Rest of Asia-Pacific Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 151. Europe Human Fibrinogen, by Country USD Million (2025-2030)
  • Table 152. Europe Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 153. Europe Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 154. Europe Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 155. Germany Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 156. Germany Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 157. Germany Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 158. France Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 159. France Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 160. France Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 161. Italy Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 162. Italy Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 163. Italy Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 164. United Kingdom Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 165. United Kingdom Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 166. United Kingdom Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 167. Netherlands Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 168. Netherlands Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 169. Netherlands Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 170. Rest of Europe Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 171. Rest of Europe Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 172. Rest of Europe Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 173. MEA Human Fibrinogen, by Country USD Million (2025-2030)
  • Table 174. MEA Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 175. MEA Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 176. MEA Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 177. Middle East Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 178. Middle East Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 179. Middle East Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 180. Africa Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 181. Africa Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 182. Africa Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 183. North America Human Fibrinogen, by Country USD Million (2025-2030)
  • Table 184. North America Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 185. North America Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 186. North America Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 187. United States Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 188. United States Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 189. United States Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 190. Canada Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 191. Canada Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 192. Canada Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 193. Mexico Human Fibrinogen, by Fibrinogen Test Results USD Million (2025-2030)
  • Table 194. Mexico Human Fibrinogen, by End Users USD Million (2025-2030)
  • Table 195. Mexico Human Fibrinogen, by Fibrinogen Deficiency USD Million (2025-2030)
  • Table 196. Research Programs/Design for This Report
  • Table 197. Key Data Information from Secondary Sources
  • Table 198. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Fibrinogen: by Fibrinogen Test Results USD Million (2018-2023)
  • Figure 5. Global Human Fibrinogen: by End Users USD Million (2018-2023)
  • Figure 6. Global Human Fibrinogen: by Fibrinogen Deficiency USD Million (2018-2023)
  • Figure 7. South America Human Fibrinogen Share (%), by Country
  • Figure 8. Asia Pacific Human Fibrinogen Share (%), by Country
  • Figure 9. Europe Human Fibrinogen Share (%), by Country
  • Figure 10. MEA Human Fibrinogen Share (%), by Country
  • Figure 11. North America Human Fibrinogen Share (%), by Country
  • Figure 12. Global Human Fibrinogen share by Players 2023 (%)
  • Figure 13. Global Human Fibrinogen share by Players (Top 3) 2023(%)
  • Figure 14. Global Human Fibrinogen share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. CSL Behring(United States) Revenue, Net Income and Gross profit
  • Figure 17. CSL Behring(United States) Revenue: by Geography 2023
  • Figure 18. Green Cross Corp. (South Korea) Revenue, Net Income and Gross profit
  • Figure 19. Green Cross Corp. (South Korea) Revenue: by Geography 2023
  • Figure 20. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Octapharma AG (Switzerland) Revenue: by Geography 2023
  • Figure 22. LFB S.A (France) Revenue, Net Income and Gross profit
  • Figure 23. LFB S.A (France) Revenue: by Geography 2023
  • Figure 24. Shanghai Xinxing Medicine Co Ltd(China) Revenue, Net Income and Gross profit
  • Figure 25. Shanghai Xinxing Medicine Co Ltd(China) Revenue: by Geography 2023
  • Figure 26. Harbin Pacific Biopharmaceutical Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 27. Harbin Pacific Biopharmaceutical Co. Ltd. (China) Revenue: by Geography 2023
  • Figure 28. ProFibrix B.V.( Netherlands) Revenue, Net Income and Gross profit
  • Figure 29. ProFibrix B.V.( Netherlands) Revenue: by Geography 2023
  • Figure 30. Shanghai Raas Blood Products Co. Ltd(China) Revenue, Net Income and Gross profit
  • Figure 31. Shanghai Raas Blood Products Co. Ltd(China) Revenue: by Geography 2023
  • Figure 32. Baxter International Inc.( United States) Revenue, Net Income and Gross profit
  • Figure 33. Baxter International Inc.( United States) Revenue: by Geography 2023
  • Figure 34. Global Human Fibrinogen: by Fibrinogen Test Results USD Million (2025-2030)
  • Figure 35. Global Human Fibrinogen: by End Users USD Million (2025-2030)
  • Figure 36. Global Human Fibrinogen: by Fibrinogen Deficiency USD Million (2025-2030)
  • Figure 37. South America Human Fibrinogen Share (%), by Country
  • Figure 38. Asia Pacific Human Fibrinogen Share (%), by Country
  • Figure 39. Europe Human Fibrinogen Share (%), by Country
  • Figure 40. MEA Human Fibrinogen Share (%), by Country
  • Figure 41. North America Human Fibrinogen Share (%), by Country
List of companies from research coverage that are profiled in the study
  • CSL Behring(United States)
  • Green Cross Corp. (South Korea)
  • Octapharma AG (Switzerland)
  • LFB S.A (France)
  • Shanghai Xinxing Medicine Co Ltd(China)
  • Harbin Pacific Biopharmaceutical Co. Ltd. (China)
  • ProFibrix B.V.( Netherlands)
  • Shanghai Raas Blood Products Co. Ltd(China)
  • Baxter International Inc.( United States)
Select User Access Type

Key Highlights of Report


Mar 2024 231 Pages 92 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Fibrinogen Quantitative research analysis
Global Human Fibrinogen Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as CSL Behring(United States), Green Cross Corp. (South Korea), Octapharma AG (Switzerland), LFB S.A (France), Shanghai Xinxing Medicine Co Ltd(China), Harbin Pacific Biopharmaceutical Co. Ltd. (China), ProFibrix B.V.( Netherlands), Shanghai Raas Blood Products Co. Ltd(China) and Baxter International Inc.( United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Several launches and approvals of new fibrinogen concentrates are expected to boost growth" is seen as one of major influencing trends for Human Fibrinogen Market during projected period 2023-2030.
The Human Fibrinogen market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Human Fibrinogen Report?

Have a Query? Click Here

Other Related Reports

Track and Trace Solutions Comprehensive Study by Type (Hardware Systems (Printing & Marking Solutions, Monitoring & Verification Solutions, Labeling Solutions, Others), Software Solution (Plant Manag...
$ 3750
Hydrokinetic Fiber Dressings Comprehensive Study by Wound (Acute wounds, Burns, Surgical & traumatic wounds, Chronic wounds, Venous leg ulcers, Pressure ulcers, Diabetic foot ulcers, Other chronic w...
$ 3800
Disruptive Behavior Disorders Comprehensive Study by Type (Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), Attention Deficit Hyperactivity Disorder (ADHD)), Application (Hospital, Clinic,...
$ 3750
Intravascular Ultrasound Comprehensive Study by Type (Consoles, Accessories), Application (IVUS Coronary Diagnostic, IVUS Coronary Intervention, IVUS Coronary Research, SFA Popliteal Diagnosis, Tibia...
$ 3750
Medical Transcription Services Comprehensive Study by Type (Online Service, Offline Service), Application (Hospitals, Clinics, Ancillary care facilities, Others), Mode of Procurement (Outsourcing, Of...
$ 3750
Drug Discovery Informatics Comprehensive Study by Type (Software, Services), Function (Sequencing and Target Data Analysis, Docking, Molecular Modeling, Libraries and Database Preparation, Other Func...
$ 3650